Dr. Emily N. Prendergast, MD

Dr. Prendergast practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Prendergast's NPI, 1780995803, was assigned on June 23, 2010. Dr. Prendergast graduated from College of Medicine - Tucson in 2010. Dr. Prendergast holds Minnesota license 61704.

Dr. Prendergast's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Prendergast's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Prendergast to 4 more medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Prendergast practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Prendergast's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Prendergast is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Prendergast's licenses on file in 6 states: Minnesota, California, Idaho, Utah, Nevada and Illinois.

Dmand AI lists hysterectomy and ovarian cyst among the conditions Dr. Prendergast treats.

CMS data shows 120 Medicare services from Dr. Prendergast across 3 procedure codes in 2024, for 61 Medicare patients. Medicare paid $8,537 for them. Every service was in an office.

CMS counts 61 Medicare patients who saw Dr. Prendergast in 2024. The largest group is 65 to 74, with 29 patients. 66% of them have high blood pressure, and 64% have high cholesterol. Their average risk score is 1.48, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Prendergast's median patient age at 62, with 98% women.

In 2024, Dr. Prendergast wrote 74 Medicare Part D claims for 32 patients. 96% of them were for generic drugs. CMS names the drug for 25 of them, across 2 drugs with 11 or more claims each, at $262 in total drug cost. In 2023, CMS named 27 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Prendergast for performance year 2024, reported as part of a group. Dr. Prendergast accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Prendergast as offering telehealth.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 9 papers to Dr. Prendergast, published from 2016 to 2023. 2020 was the busiest year, with 2. The most frequent topics are Ovarian Neoplasms, Genital Neoplasms, Female and Carcinoma, Ovarian Epithelial. Dr. Prendergast has published most often in Gynecol Oncol. Dr. Prendergast's most frequent co-authors are Joshua Garrett Cohen, MD, Sharad Anant Ghamande, MD and Bradley J. Monk, MD.

CMS Open Payments shows 38 general payments to Dr. Prendergast from 6 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 48% of the total. Intuitive Surgical, Inc. paid the most, $5,281.

Dr. Prendergast serves on SGO-Legislation and Regulation Committee.

Dr. Prendergast graduated from College of Medicine - Tucson in 2010. Dr. Prendergast is a member of AOA, American College of Obstetricians and Gynecologists, ASCO and Society of Gynecologic Oncology.

Dr. Prendergast is in network with 20 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.